Skip to content
type1.science
Phase 1/2RecruitingNCT07199946

Verapamil to preserve residual insulin secretion in children

Phase 1/2 pediatric trial of verapamil for residual insulin preservation after recent-onset T1D.

Primary endpoints

  • Change in C-peptide AUCmean 0-120 min) during an MMTT from baseline to month 24.
  • Number of participants with treatment-related adverse events as assessed by CTCAE v4.0".

Results so far

No results posted yet.